Having identified the PDGFRβ-STAT5 axis as an important oncogenic driver in ALCL, we next assessed the efficacy of the STAT inhibitor AC-4-130 in vivo. This evidence concerns the gene PDGFRB and anaplastic large cell lymphoma.